EffRx Pharmaceuticals Statement on COVID-19
The globe has literally gone into quarantine due to the COVID-19 outbreak. This is an unprecedented crisis situation in terms of breadth and scale, from a global health, social and economic standpoint.
While committed to keep our core activities unaffected, EffRx has implemented measures aimed at guaranteeing business operation continuity, with particular focus on the supply of Binosto® to our customers. EffRx has engaged with its suppliers and clients to ensure continuity of the business and will continue to monitor the situation as it evolves with the aim to minimize the impact of this crisis on our business.
EffRx has further taken internal measures to reduce the contamination risk for employees and business partners. The health of our staff and partners is our number one priority. The entire staff is working remotely from home with effective equipment & systems. We have also cancelled all travels, replaced face-to-face meetings/trainings by virtual meetings and are pursuing digital collaboration with all our stakeholders.
We thank for your loyalty, flexibility and understanding for the unforeseen consequences of this global pandemic. We are in this together.
Wishing you all good health.
29 February 2020 will be the 13th international Rare Disease Day coordinated by EURORDIS
Rare Disease Day takes place on the last day of February each year. The main objective of Rare Disease Day is to raise awareness amongst the general public and decision-makers about rare diseases and their impact on patients’ lives.
Building awareness of rare diseases is so important because 1 in 20 people will live with a rare disease at some point in their life. Despite this, there is no cure for the majority of rare diseases and many go undiagnosed. Rare Disease Day improves knowledge amongst the general public of rare diseases while encouraging researchers and decision makers to address the needs of those living with rare diseases.
Learn more about Rare Disease Day here.
EffRx Pharmaceuticals Attending the 38th Annual J.P. Morgan Healthcare Conference from January 13-16, 2020 in San Francisco
The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.
Meet the EffRx Team at the 25th Annual BIO-Europe International Conference from November 11-13, 2019 in Hamburg
EffRx will be attending Europe’s largest life science partnering conference, BIO-Europe, which offers countless opportunities to engage with global life science partners. This year´s BIO-Europe partnering event will again draw over 4,000 industry attendees from over 60 countries, representing more than 2,000 companies for three days of high-level networking.
To set up a meeting, please contact us via the partnering platform or at email@example.com.
EffRx to Attend the Medical Meeting: Bisphosphonates2019, Celebrating 50 Years from 15-17th July 2019 in Sheffield, UK
EffRx Pharmaceuticals SA is proud to announce that it will attend the upcoming medical meeting bisphosphonates2019 – Celebrating 50 years, taking place 15-17th of July 2019 in Sheffield, UK. The year 2019 marks 50 years since the first publication on the biological effects of the bisphosphonates. The meeting which focuses 100% on bisphosphonates will review developments over the past 50 years, discuss our current understanding and look at what the future may hold.
EffRx Pharmaceuticals SA is also pleased to inform that new safety data on Binosto® will be presented at the Bisphosphonates2019 medical meeting. The data will be presented as a poster and oral snap presentation titled “Upper Gastrointestinal Safety with the Buffered Solution of Alendronate 70 mg: 6 Years of Post-Marketing Experience” authored by B. Cortet, P. Fardellone, L. Zakin, E. Fink Eriksen on Monday, 15th of July 2019, at 12:55 pm (poster #40).
The authors of the new Binosto® safety data conclude that Binosto® is associated with a lower frequency of upper gastrointestinal adverse reactions than reported for alendronate tablets and that it is a well-tolerated oral bisphosphonate for the management of osteoporosis.
“The safety data, after 6 years of post-marketing experience, reinforce that Binosto® is a well-tolerated oral bisphosphonate for the management of osteoporosis,” says Dr Lorraine Zakin, Medical Affairs Director at EffRx Pharmaceuticals.
EffRx looks forward to seeing you at the Bisphosphonates2019 in Sheffield!
About EffRx Pharmaceuticals SA
EffRx Pharmaceuticals SA is a commercial-stage functionally integrated pharmaceutical company, based in Switzerland, that develops and commercializes niche & orphan medicines in Europe. EffRx aims to be the preferred accelerator for late clinical & regulatory development, approval, valorization of niche & orphan medicines in Europe and Switzerland.
Our lead commercialized product, Binosto® is indicated for the treatment of osteoporosis. Binosto® (alendronate 70 mg effervescent tablets) is the first and only buffered solution for the treatment of postmenopausal osteoporosis. It reduces the risk of hip, spine, and non-spine fractures.1 The buffered solution with high acid-neutralizing capacity minimizes the risk of exposing the esophagus (in case of reflux) and the stomach to acidified alendronate.2,3 Binosto® is taken once a week as an easy-to-swallow, buffered solution with no risk of a tablet getting lodged in the esophagus. Binosto® has the potential to improve adherence to therapy4, thereby decreasing the risk of disabling fractures.
Statements made here are according the approved Binosto Summary of Product Characteristics in Europe. Please refer to the Binosto®/Steovess® prescribing information and approved indications, contraindications, and warnings in your country.
- Black DM et al. Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial. J Clin Endocrinol Metab 2000;85:4118-4124.
- Binosto Summary of Product Characteristics. 2017.
- Hodges LA et al. Modulation of gastric pH by a buffered soluble effervescent formulation: A possible means of improving gastric tolerability of alendronate. Int J Pharm 2012;432:57-62.
- Giusti A et al. Persistence with the buffered solution of alendronate 70 mg: prospective observational study. Osteoporos Int 2018;29(S1):S431.
Media Contact: Pamela Saredi, firstname.lastname@example.org
Meet EffRx Pharmaceuticals at the BIO International Convention from June 3-6, 2019 in Philadelphia
BIO International Convention is back in Philidelphia, June 3-6, to celebrate history-making innovation and EffRx will take part. This is the only event where one can access the global biotech and pharma community via Partnering and network with 16,000+ attendees from 67 countries.
Binosto® Booth a Success at the WCO-IOF-ESCEO Congress in Paris
EffRx would like to thank everyone who helped make the Binosto® booth a success at the 19th Edition of the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases. With more than 4,000 delegates, the WCO-IOF-ESCEO Congress was an optimal platform for showcasing our lead product Binosto®.
Rare Disease Day is on February 28, 2019 – Help Raise Awareness
The main objective of Rare Disease Day is to raise awareness amongst the general public and decision-makers about rare diseases and their impact on patients’ lives.
The campaign targets primarily the general public and also seeks to raise awareness amongst policy makers, public authorities, industry representatives, researchers, health professionals and anyone who has a genuine interest in rare diseases.
Rare Disease Day was launched by EURORDIS-Rare Diseases Europe and its Council of National Alliances in 2008.
Meet the EffRx Team at the 24rd Annual BIO-Europe International Conference from 5-7 November 2018 in Copenhagen
The 24th annual BIO-Europe is Europe’s largest partnering conference serving the global biotechnology industry. Delegates from all parts of the biotechnology value chain come to BIO-Europe to quickly identify, engage and enter into strategic relationships that drive their businesses successfully forward. Investment and collaboration opportunities developed in prior BIO-Europe conferences have produced many highly successful business partnerships.
This year´s BIO-Europe partnering event will again draw over 4,000 industry attendees from over 60 countries, representing more than 2,100 companies for three days of high level networking.
To set up a meeting, please contact us via the partnering platform or at email@example.com.
World Osteoporosis Day – WOD, on October 20th: Help Spread the Word
World Osteoporosis Day – WOD, marked on October 20th each year, is year-long campaign dedicated to raising global awareness of the prevention, diagnosis and treatment of osteoporosis and related musculoskeletal disease.
It aims to put bone health and fracture prevention on the global health agenda and reaches out to health-care professionals, the media, policy makers, patients, and the public at large.
Some Facts About Osteoporosis:
- By 2050, the worldwide incidence of hip fracture in men is projected to increase by 310% and by 240% in women.
- Osteoporosis accounts for more days in the hospital than breast cancer, heart attack, diabetes & other diseases.
- Loss of independence after a hip fracture, approximately 60% require assistance a year later and 20% will require long-term nursing care.
- Fracture risk up to 27% higher than prostate cancer risk.
- Aged 50+ 1/3 women 1/5 men: will suffer an osteoporotic fracture worldwide.
Knowing your risk factors
Take the IOF One-Minute Osteoporosis Risk Test to find out whether you may have specific factors which place you at higher risk of osteoporosis and fractures.
EffRx commitment to bone health:
Although a small-scale company, EffRx’s employees have made personal efforts to make some noise on behalf of the WOD. Each employee has asked relatives, friends and acquaintances throughout October to support the IOF Global Patient Charter (https://www.iofbonehealth.org/iof-global-patient-charter)
Additionally, in honor of World Osteoporosis Day, EffRx organized a company bone-healthy-brunch on October 16th. Although bone-healthy nutrition is important – particularly to build maximum peak bone mass in adolescents -, drug therapies are critical for fracture prevention in people at high risk of fracture. Today, there are many proven and effective treatments which have been shown to reduce the risk of osteoporotic fracture by between 30–50%.
Meet EffRx at the BIO International Convention from June 4-7, 2018 in Boston
BIO International Convention is back in Boston, June 4-7, to celebrate history-making innovation and EffRx will take part. This is the only event where one can access the global biotech and pharma community via Partnering and network with 16,000+ attendees from 74 countries.
EffRx to Showcase Binosto® at WCO-IOF-ESCEO 2018 in Krakow, Poland
EffRx Pharmaceuticals SA is proud to announce that it will participate in the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases in Krakow, Poland, from 19 to 22 April 2018. The WCO-IOF-ESCEO Congress is the world’s leading clinical conference on bone, joint and muscle health and therefore the ideal venue for EffRx to showcase its flagship product Binosto®, the only buffered soluble alendronate for the treatment of postmenopausal osteoporosis. Learn more
European market-entry strategy for biopharma companies
The European pharmaceutical market offers many opportunities for U.S. biopharmaceutical companies. An early engagement as well as a visceral understanding of the heterogeneity of the European market are key to succeed. Partnering with EffRx Pharmaceuticals, a commercial-stage pharmaceutical company offers various advantages. Because of its diversity and non-bureaucratic access to a talented workforce, EffRx an ideal partner to kick off your international go-to-market strategy.
Meet the EffRx Team at the 23rd Annual BIO-Europe International Conference from 6-8 November 2017 in Berlin
The 23rd Annual BIO-Europe International Conference is the “must-attend” event and Europe’s largest life science partnering conference. And EffRx will be there.
The conference brings together hundreds of the world’s most innovative leaders across biotech, finance and pharma for high-level networking, pre-scheduled partnering meetings, strategic panel discussions and more.
To arrange for a meeting, please contact us via the BIO-Europe partnering platform.
Meet EffRx Pharmaceuticals at the BIO International Convention in San Diego, 19-22. June 2017
EffRx will participate in the parterning forum at the BIO International Convention (BIO). BIO attracts 16,000 biotechnology and pharma leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships. They bring together a wide spectrum of life science and application areas including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy.
Binosto data to be presented at the WCO-IOF-ESCEO Congress in Florence
EffRx Pharmaceuticals SA is proud to announce that it will participate in the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases in Florence, Italy, from 23 to 26 March 2017. The WCO-IOF-ESCEO Congress, as it is also known, is the world’s leading clinical conference on bone, joint and muscle health and therefore the ideal venue for EffRx to showcase its flagship product Binosto, the world’s first and only buffered soluble alendronate for the treatment of postmenopausal osteoporosis. Medical professionals from around the world will be able to learn more about Binosto and its exciting properties at the Binosto booth in the exhibition area (booth #21).
EffRx Pharmaceuticals SA is equally thrilled to inform that it will present the latest safety data on Binosto at the WCO-IOF-ESCEO Congress. The data will be presented in the poster area on 24 March 2017, from 14:00 to 15:00 (poster #589).
Please join EffRx at the WCO-IOF-ESCEO Congress in Florence!
Bone markers as screening strategy for patient adherence to osteoporosis medications
IOF-ECTS Position Paper provides recommendations for the screening of adherence to oral bisphosphonates; proposes assessment using PINP and CTX bone turnover markers (BTMs) at baseline and after three months.
Oral bisphosphonates are common first line treatments for osteoporosis. However, approximately half of patients who begin osteoporosis treatment do not follow their prescribed treatment and/or discontinue treatment within a year. Identifying low adherence to medication – a problem commonly seen with many chronic diseases – is a critical issue as it jeopardizes the efficacy of treatment, leaving osteoporosis patients unprotected against fractures.
For the complete news story, visit the International Osteoporosis Foundation online.
EffRx Pharmaceuticals Attending the 35th Annual J.P. Morgan Healthcare Conference
EffRx Pharmaceuticals will be attending the 35th Annual J.P. Morgan Heathcare Conference to take place from January 9-12, 2017 at the Westin St. Francis Hotel in San Francisco, California. To arrange for a meeting, please contact us at firstname.lastname@example.org
Meet the EffRx Team at BIO-Europe 2016 in Cologne, Germany on Nov. 7-9, 2016
EffRx Pharmaceuticals will be attending the 22nd Annual International Partnering Conference in Cologne, Germany. BIO-Europe is Europe’s largest partnering conference serving the global biotechnology industry. To arrange for a meeting with us, please contact us via the BIO-Europe partnering platform or at email@example.com
EffRx Announces Changes in the Composition of the Board of Directors
Freienbach, June 14th, 2016 — EffRx Pharmaceuticals SA, a specialty pharmaceutical company focused on the development of novel therapeutic entities for orphan and specialty indications, today announced the appointment of Dr. Jonas Ekblom as Chairman and Dr. Alcide Barberis as Member of the Board of Directors.
“I feel elated to join the Board of this exciting company and I look forward to working with the Management team and the Board of Directors as we progress EffRx into its next phase of consolidation, maturation and growth,” commented Dr. Jonas Ekblom, Chairman.
Dr. Ekblom and Dr. Barberis will be replacing Mr. Oscar Ahlgren, Mr. Carl-Gustaf Johansson and Mr. Thomas Mårtensson who have stepped down from their current role as Directors. During their tenure they have successfully managed the transition of EffRx to become an integrated pharmaceutical company with its flagship program, Binosto®, being now commercialized in 10 key countries across Europe, Asia and America. Mr. Anders Wiklund will continue to serve as a Board Director and with his accomplished industry experience will ensure a smooth transition within the Board.
Dr. Jonas Ekblom brings over 20 years of experience from the life science sector, with a focus in pharmacology and drug development. He has managed R&D programs in in several therapeutic areas. Dr. Ekblom has business experience from US, EU and Asia.
Dr. Alcide Barberis is a biotech entrepreneur and manager with over 20 years management experience in the biotechnology industry and scientific experience in the private and public research sectors.